No-deal Brexit turned down with 149 vote defeat in UK Parliament
Category: #headlines  By Mateen Dalal  Date: 2019-03-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

No-deal Brexit turned down with 149 vote defeat in UK Parliament

In a recent turn of events, a day after Prime Minister of Britain Theresa Mays Brexit bill was turned down with 149 votes defeat, Members of the Parliament are back to the House of Commons to decide on whether to avert the UKs exodus from the EU by 29th March deadline without any pact in place.

If reports are to be believed,  the recent act to try and prevent the no-deal Brexit, that would witness the United Kingdom crash out of the twenty-eight member economic bloc with no transition phase, comes after the refusal of Theresa May's withdrawal contract 391 to 242 in spite of a final push by her to try and persuade hard-Brexiteers that the concessions won by her to the controversy-backed Irish backstop part would not see Britain tied to European Union guidelines indefinitely.

According to May’s address during her weekly Prime Minister's Questions on Wednesday, she believes that she may not have her own voice but she understands the voice of the nation.

She further mentioned that she considers that they have a good deal, as no deal is better than a bad deal. But she had been working towards leaving on 29 March with a good deal, she added.

The motion tabled by her to be chosen on the evening of Wednesday states that the house disapproves to favor parting the EU without a withdrawal contract and an agenda on the future association on 29 March, cite trusted sources.

If, as anticipated, MPs discard the no-deal Brexit on 29 March in the final poll on the government motion, May would be required to declare how she plans to proceed, claim market experts. Opposing groups of MPs are consequently looking to influence the procedure by tabling revisions to any motion the government presents at this stage.

Reportedly, although few hard-Brexiteers including prior Cabinet Minister Boris Johnson are in favor of a no-deal exit, the majority for it in the Parliament is unlikely.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Arranta Bio acquires Captozyme to accelerate microbiome development
Arranta Bio acquires Captozyme to accelerate microbiome development
By Mateen Dalal

Arranta has established a Center of Excellence for microbiome development   The acquisition will help quicken the delivery of LBPs for clients worldwide Arranta Bio, a leading Contract Development Manufacturing Organization, recently annou...

CytoDyn obtains IRB approval for leronlimab for patients with TNBC
CytoDyn obtains IRB approval for leronlimab for patients with TNBC
By Mateen Dalal

Reports confirm that CytoDyn Inc., a late-stage biotechnology company has announced that it has recently received approval from the Institutional Review Board for leronlimab, to be directed to triple-negative breast cancer (TNBC) patients under a com...

FDA declines approval of Lipocine’s oral drug Tlando for third time
FDA declines approval of Lipocine’s oral drug Tlando for third time
By Mateen Dalal

FDA declines approval of Lipocine’s oral drug Tlando for third time Reportedly, the oral drug Tlando was first declined  approval by FDA in the year 2016. The U.S. Food and Drug Administration (FDA)  declined the approval of oral dr...